Abstract:Ovarian cancer is the fifth leading cause of cancer death and has the highest mortality rate of all gynecologic malignancies.The majority of patients with ovarian cancer present with advanced disease(stages III-IV) only have a 5-year survival of 5%～20%.The survival of patients with stages I-II disease ranges from 60%～90%,depending on tumor grade.It suggests the importance of developing new treatment and the early diagnostic method for ovarian cancer.The folate receptor α(FRα),a 38 ku molecule,belongs to the folate receptor(FR) family with high affinity for folates.FRα is anchored to cell membranes through a glycosylphosphatidylinositol moiety and transports folates via an endocytic process.FRα exhibits the limited normal tissue distribution but is overexpressed in a spectrum of solid tumors,especially in ovarian cancer.It is reported that FRα overexpressed in >90% of ovarian cancers at levels 10-to 100-fold higher than its normal expression,and the expression level of FRα in ovarian cancers correlates with the grade of malignancy.Even in early stage of ovarian cancer,FRα could be detected.The prevalent expression of FRα in ovarian cancer,among all stages,has stimulated interest in applying it as a early diagnostics biomarker.A number of studies have examined the expression of FRa in malignant tissues by immunohistochemistry.Additionally,an immunoblot assay was employed to confirm ovarian cancer patients demonstraing elevated levels of FRa in the circulation system.Furthermore,therapeutic agents based on FRα have been developed.A humanized monoclonal antibody MORAb-003 against FRα possesses novel,growth-inhibitory functions on cells overexpressing FRα.In addition,MORAb-003 elicited robust antibody-dependent cellular cytotoxicity(ADCC) and complement-dependent cytotoxicity(CDC) in vitro,and inhibited the growth of human ovarian tumor xenografts in nude mice.The novel folate targeted therapies may hold promise for the majority of women with either newly diagnosed or recurrent ovarian cancer.

Construction and Identification of Eukaryotic Expression Vector Encoding Folate Receptor

Construction and Identification of Lentiviral Vector-mediated RNA Interference of Epidermal Growth Factor Receptor

[Establishment of C26 Cell Strain Stably Expressing Folate Receptor Α].

Construction of human recombinant Oct3/4 eukaryotic expression vectors and their expression in ovarian cancer cells

Construction of VEGF111b expression vector and preparation of VEGF111b antibody

Identification of a Peptide for Folate Receptor Alpha by Phage Display and Its Tumor Targeting Activity in Ovary Cancer Xenograft

Construction and Identification of Eukaryotic Expression Vector of Folate Binding Proteins 1

Construction of MicroRNA-22 Eukaryotic Expression Vector and Stable Expression in Ovarian Cancer Cell Line SKOV-3

Construction and Identification of FAK RNAi Lentiviral Vector

Construction and Identification of Shrna Expression Vector for Human Rac1 Gene

Gene delivery with active targeting to ovarian cancer cells mediated by folate receptor α

The Folate Receptor α and Ovarian Cancer

Construction and Identification of Eukaryotic Expression Vector of pcDNA3-UHRF1

Construction of Eukaryotic Expression Vector Encoding Human Nasopharyngeal Carcinoma Anti-Idiotype Antibody Single Chain Fragment Gene G22 and Its Expression

Construction and Identification of Recombinant Lentiviral Expressing Vectors Formyl-Coa Transferase Gene and Oxalyl-CoA Decarboxylase Gene of Oxalobacter Formigenes from Chinese Feces

Construction and identification of human ovarian carcinoma cDNA phage expression library

Expression of Folate Receptor Alpha in Ovarian Epithelial Tumors

Construction and Verification D Recombinant Follicle-specific Expression Vector

Construction and expression of eukaryotic expression vector containing gene E2F3

Construction of anti-CD3 scFv-B7.1 eukaryotic expression vector and preliminary expression in COS-7 cells

Construction of eukaryotic vector of human sTNFR1